Stockpolly
Search
Delisting risk
RNAZ · NASDAQ · Biotechnology

TransCode Therapeutics (RNAZ)

Develops RNA-delivery and immuno-oncology candidates for metastatic and other cancers.

$2.01
At close−0.05 (−2.43%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
5435253451677
Research & development33231423355,1074
21221112122,2223
General & administrative00220112122,2223
Other expenses000—00—009−7,3211
Operating income−5−4−3−5−2−5−3−4−5−16−7−7
00000−1−9003−100
Interest income000000000000
Interest expense000000000000
Other non-operating income000001900−3100
Income before tax−5−4−3−5−2−6−12−4−5−13−18−7
Income tax expense000000000000
Net income from continuing operations−5−4−3−5−2−6−12−4−5−13−18−7
Other adjustments000000000000
Net income−5−4−3−5−2−6−12−4−5−13−18−7
EPS, basic−$48.44−$761.16−$21.45−$24.42−$6.52−$16.61−$70.28−$5.13−$5.82−$16.42−$21.28−$7.17
EPS, diluted−$48.44−$761.16−$21.45−$24.42−$6.52−$16.61−$70.28−$5.13−$5.82−$16.42−$21.28−$7.17
Weighted average shares, basic000000011111
Weighted average shares, diluted000000011111
EBITDA−5−4−3−5−2−6−12−4−5−13−18−7
Depreciation & amortization000000000000
EBIT−5−4−3−5−2−6−12−4−5−13−18−7